Preventing Oral Mucositis with Hybrid Adenoretroviral Vectors
Posted Jun 13 2010 5:00pm
Description of Invention: Researchers at the National Institutes of Health have recently developed a novel method utilizing adenoretroviral vectors to safely and swiftly prevent oral mucositis induced by radiotherapy. This clever new method developed by National Institute of Dental and Craniofacial Research (NIDCR) researchers combines the advantages of adenoviral and retroviral vectors to efficiently shuttle into salivary glands a non-integrating vector that can produce a therapeutic protein for intermediate to long-term treatment. This approach is anticipated to result in fewer side-effects than current therapies.
The market for the treatment of mucositis, the painful inflammation and ulceration of the mucous membranes lining the digestive tract, is estimated to be in excess of $5 billion world-wide. Up to 80% of all patients receiving radiotherapy and approximately 40% of all chemotherapy patients develop oral mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis.
Prevention of radiation-induced oral mucositis
Transduction of genes encoding secretory proteins with clinical uses for intermediate to long-term treatment (e.g., 4-8 weeks)
Reduced potential for side-effects
Efficient production of transduced genes
Efficient in vivo/in vitro transduction
Development Status: Pre-clinical
Inventors: Changyu Zheng (NIDCR)
Licensing Status: Available for licensing.
Collaborative Research Opportunity: The National Institute of Dental and Craniofacial Research is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact David Bradley, Ph.D. at 301-402-0540 or firstname.lastname@example.org for more information.
Portfolios: Gene Based Therapies Gene Based Therapies - Therapeutics In-vitro Data
For Additional Information Please Contact: Patrick McCue Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: McCuepat@mail.nih.gov Phone: 301-496-7057 Fax: 301-402-0220